Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

NCT03374488 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

UC (Urothelial Cancer)

Interventions

DRUG: Pembrolizumab
DRUG: Epacadostat
DRUG: Placebo

Sponsor

Incyte Corporation

Collaborators

[object Object]